Reirradiation using helical tomotherapy-based hypofractionated stereotactic radiotherapy for 19 brain metastases after the second recurrence of distant brain failure: a case report and literature review.
Tao Wang, Hongfu Zhao, Rafal Suwinski, Guanghui Cheng, Wei Guan
{"title":"Reirradiation using helical tomotherapy-based hypofractionated stereotactic radiotherapy for 19 brain metastases after the second recurrence of distant brain failure: a case report and literature review.","authors":"Tao Wang, Hongfu Zhao, Rafal Suwinski, Guanghui Cheng, Wei Guan","doi":"10.21037/tlcr-2024-1151","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>A definitive optimal oncologic care regimen for recurrent multiple brain metastases (BMs) has yet to be established, and the accrual of high-quality evidence pertaining to helical tomotherapy-based stereotactic radiotherapy (HT-SRT) in patients with BMs is needed.</p><p><strong>Case description: </strong>We treated a 64-year-old male smoker initially diagnosed with non-small cell lung cancer (NSCLC) with BMs, and the initial schedule involved administering linear accelerator-based hypofractionated stereotactic radiotherapy (Linac-HSRT) targeting 6 intracranial lesions. Further chemotherapy was declined due to intolerance after one cycle of paclitaxel-albumin/carboplatin. Distant brain failure (DBF) and extracranial progression emerged 3 months subsequent to the initial SRT, and helical tomotherapy-based hypofractionated stereotactic radiotherapy (HT-HSRT) was replanned to 4 BMs, while helical tomotherapy-based intensity-modulated radiotherapy was employed for the extracranial lesions. Nevertheless, reirradiation with hippocampal-sparing HT-HSRT and simultaneous memantine approach were imminently delivered for confirmed DBF, as 19 newly identified intact intracranial lesions were observed at 5 months posttreatment. As assessed by the Hopkins Verbal Learning Test Revised Total Recall test, neither severe symptomatic radionecrosis (RN) nor neurocognitive dysfunction has manifested thus far, representing a survival period of 20.5 months. In the literature review, SRT delivery schedule to BMs, strategies for managing recurrent BMs and addressing RN, along with 6 summarized published studies of HT-SRT for BM were discussed.</p><p><strong>Conclusions: </strong>We posit that the administration of repeated SRT for recurrent BMs in a short-term interval may be viable, yet randomized, robust analyses are imperative to ascertain the potential benefits of HT-SRT in preserving neurocognition and confirm the efficacy of memantine and hippocampal avoidance during SRT.</p>","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":"14 1","pages":"272-286"},"PeriodicalIF":3.5000,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11826268/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational lung cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tlcr-2024-1151","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/22 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: A definitive optimal oncologic care regimen for recurrent multiple brain metastases (BMs) has yet to be established, and the accrual of high-quality evidence pertaining to helical tomotherapy-based stereotactic radiotherapy (HT-SRT) in patients with BMs is needed.
Case description: We treated a 64-year-old male smoker initially diagnosed with non-small cell lung cancer (NSCLC) with BMs, and the initial schedule involved administering linear accelerator-based hypofractionated stereotactic radiotherapy (Linac-HSRT) targeting 6 intracranial lesions. Further chemotherapy was declined due to intolerance after one cycle of paclitaxel-albumin/carboplatin. Distant brain failure (DBF) and extracranial progression emerged 3 months subsequent to the initial SRT, and helical tomotherapy-based hypofractionated stereotactic radiotherapy (HT-HSRT) was replanned to 4 BMs, while helical tomotherapy-based intensity-modulated radiotherapy was employed for the extracranial lesions. Nevertheless, reirradiation with hippocampal-sparing HT-HSRT and simultaneous memantine approach were imminently delivered for confirmed DBF, as 19 newly identified intact intracranial lesions were observed at 5 months posttreatment. As assessed by the Hopkins Verbal Learning Test Revised Total Recall test, neither severe symptomatic radionecrosis (RN) nor neurocognitive dysfunction has manifested thus far, representing a survival period of 20.5 months. In the literature review, SRT delivery schedule to BMs, strategies for managing recurrent BMs and addressing RN, along with 6 summarized published studies of HT-SRT for BM were discussed.
Conclusions: We posit that the administration of repeated SRT for recurrent BMs in a short-term interval may be viable, yet randomized, robust analyses are imperative to ascertain the potential benefits of HT-SRT in preserving neurocognition and confirm the efficacy of memantine and hippocampal avoidance during SRT.
背景:复发性多发性脑转移瘤(BMs)的明确最佳肿瘤护理方案尚未建立,需要积累高质量的证据,这些证据与基于螺旋ct的立体定向放疗(HT-SRT)在脑转移瘤患者中的应用有关。病例描述:我们治疗了一名64岁的男性吸烟者,最初诊断为非小细胞肺癌(NSCLC)伴脑转移,最初的治疗计划包括给予基于线性加速器的低分割立体定向放疗(Linac-HSRT),靶向6个颅内病变。在紫杉醇-白蛋白/卡铂治疗一个周期后,由于不耐受,进一步化疗被拒绝。首次SRT后3个月出现远性脑衰竭(DBF)和颅外进展,重新计划以螺旋断层为基础的低分割立体定向放疗(HT-HSRT)为4个脑转移灶,而以螺旋断层为基础的调强放疗则用于颅外病变。然而,由于在治疗后5个月观察到19个新发现的完整颅内病变,对于确诊的DBF,立即采用保留海马的HT-HSRT和同时美金刚入路进行再照射。经Hopkins Verbal Learning Test Revised Total Recall Test评估,迄今未出现严重症状性放射性坏死(RN)或神经认知功能障碍,生存期为20.5个月。在文献综述中,我们讨论了脑转移的SRT交付时间表、复发性脑转移的管理策略和解决RN问题,以及6篇总结发表的关于脑转移HT-SRT的研究。结论:我们认为短期内对复发性脑转移进行重复SRT可能是可行的,但随机、稳健的分析是必要的,以确定HT-SRT在保持神经认知方面的潜在益处,并确认在SRT期间美金刚和海马回避的有效性。
期刊介绍:
Translational Lung Cancer Research(TLCR, Transl Lung Cancer Res, Print ISSN 2218-6751; Online ISSN 2226-4477) is an international, peer-reviewed, open-access journal, which was founded in March 2012. TLCR is indexed by PubMed/PubMed Central and the Chemical Abstracts Service (CAS) Databases. It is published quarterly the first year, and published bimonthly since February 2013. It provides practical up-to-date information on prevention, early detection, diagnosis, and treatment of lung cancer. Specific areas of its interest include, but not limited to, multimodality therapy, markers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to lung cancer.